Posted in Clinical Data AZ is three for three with COPD hope tozorakimab April 20, 2026 Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story